Focus: oral peptide delivery and innovative formulations enabled by the SPID® platform
LXM.2 is Laxxon's focus program: SPID®-printed oral GLP-1 RA microtablets in preclinical development, with Phase 1 planned for 2027 (press release of October 21, 2026).
Pipeline →